Knowledge graph · Cancer
Colon Neoplasm
subtype
- Identifier
- CI-CAN-00004992
- Entity page
- /cancer/colon-neoplasm ↗
- Edges
- 2,144
- Neighbours
- 15 genes21 drugs10 trials
- Drawn
- 46 of 46 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Colon Neoplasm approved for …APPROVED_FOR9 of 8 | ||||||||
| ← approved for | Capecitabinesmall_molecule 4 source records aggregated | supports | mesh_therapeutic_area | Colon Neoplasm | 4 | Regulatory | ema | graph → |
| ← approved for | Fluorouracilsmall_molecule FDA (US) · approved · 2026-02-20 · FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum | |||||||